VLA 0.00% $1.75 viralytics limited

VLA Valuation, page-2

  1. 91 Posts.
    lightbulb Created with Sketch. 15
    Mercks revenue from Keytruda in the Oct 17 quarter was US$1billion, so extrapolating the yearly revenue will be US$4billion so if Cavatak makes Keytruda 10% more sales Merck will have made their money in a year (give or take the cost of finalizing the approvals). Given that Cavatak actually showed better efficacy and safety profiles in 2015 than their product this valuation seems cheap.
    Last edited by 3rddoor: 23/02/18
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.